Skip Navigation



JAC Advance Access published online on October 22, 2002
Journal of Antimicrobial Chemotherapy, doi:10.1093/jac/dkf207
© 2002 by The British Society for Antimicrobial Chemotherapy
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
50/5/747    most recent
dkf207v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Rana, B.
Right arrow Articles by Tobin, C. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rana, B.
Right arrow Articles by Tobin, C. M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2002 The British Society for Antimicrobial Chemotherapy

In Brief

Linezolid penetration into osteo-articular tissues

B. Rana 1, I. Butcher 2, P. Grigoris 1, C. Murnaghan 1, R. A. Seaton 3, C. M. Tobin 4

1 University Department of Orthopaedics, Western Infirmary and Gartnavel General Hospital, Dumbarton Road, Glasgow G11 6NT, UK
2 Department of Microbiology, Western Infirmary and Gartnavel General Hospital, Dumbarton Road, Glasgow G11 6NT, UK
3 Department of Infectious Diseases, Western Infirmary and Gartnavel General Hospital, Dumbarton Road, Glasgow G11 6NT, UK
4 Bristol Centre for Antimicrobial Research and Evaluation, Department of Microbiology, Southmead Hospital, Bristol BS10 5NB, UK

Received 8 November 2001 ; revised 29 July 2002 ; accepted 19 August 2002

Abstract

Penetration of linezolid into osteo-articular tissue and fluid was studied in 10 patients undergoing primary total knee replacement. Linezolid 600 mg 12 hourly was given orally over the 48 h before operation and intravenously 1 h before induction of anaesthesia. Mean concentrations of linezolid at 90 min after the final dose, in serum, synovial fluid, synovium, muscle and cancellous bone, assayed by HPLC, were at least twice the MIC90 for staphylococci and streptococci. The concentrations obtained indicate good penetration of this antibiotic and support its use in the management of multidrug-resistant Gram-positive bone, joint and deep-seated soft-tissue infections.

Keywords: linezolid, oxazolidinone, bone and joint infection, osteomyelitis, osteo-articular tissue, pharmacokinetics
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J Antimicrob ChemotherHome page
G. E. Stein, S. Schooley, C. A. Peloquin, A. Missavage, and D. H. Havlichek
Linezolid tissue penetration and serum activity against strains of methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility in diabetic patients with foot infections
J. Antimicrob. Chemother., October 1, 2007; 60(4): 819 - 823.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
C. Buerger, N. Plock, P. Dehghanyar, C. Joukhadar, and C. Kloft
Pharmacokinetics of unbound linezolid in plasma and tissue interstitium of critically ill patients after multiple dosing using microdialysis.
Antimicrob. Agents Chemother., July 1, 2006; 50(7): 2455 - 2463.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
J. Weigelt, K. Itani, D. Stevens, W. Lau, M. Dryden, C. Knirsch, and the Linezolid CSSTI Study Group
Linezolid versus Vancomycin in Treatment of Complicated Skin and Soft Tissue Infections
Antimicrob. Agents Chemother., June 1, 2005; 49(6): 2260 - 2266.
[Abstract] [Full Text] [PDF]

Home page
 Journal of Pharmacy PracticeHome page
C. Schriever, L. Zeitz-Colaizzi, A. Quinn, A. E. Schriever, and J. P. Cannon
Considerations for the Management of Gram-Positive Pathogens in the Intensive Care Unit
Journal of Pharmacy Practice, April 1, 2005; 18(2): 100 - 108.
[Abstract] [PDF]

Home page
 J Antimicrob ChemotherHome page
M. Bassetti, F. Vitale, G. Melica, E. Righi, A. Di Biagio, L. Molfetta, F. Pipino, M. Cruciani, and D. Bassetti
Linezolid in the treatment of Gram-positive prosthetic joint infections
J. Antimicrob. Chemother., March 1, 2005; 55(3): 387 - 390.
[Abstract] [Full Text] [PDF]

Home page
 Mayo Clin Proc.Home page
R. R. Razonable, D. R. Osmon, and J. M. Steckelberg
Linezolid Therapy for Orthopedic Infections
Mayo Clin. Proc., September 1, 2004; 79(9): 1137 - 1144.
[Abstract] [PDF]

Home page
 J Antimicrob ChemotherHome page
E. S. R. Darley and A. P. MacGowan
Antibiotic treatment of Gram-positive bone and joint infections
J. Antimicrob. Chemother., June 1, 2004; 53(6): 928 - 935.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
F. Kutscha-Lissberg, U. Hebler, G. Muhr, and M. Koller
Linezolid Penetration into Bone and Joint Tissues Infected with Methicillin-Resistant Staphylococci
Antimicrob. Agents Chemother., December 1, 2003; 47(12): 3964 - 3966.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
D. Nathwani, G. D. Barlow, K. Ajdukiewicz, K. Gray, J. Morrison, B. Clift, A. J. France, and P. Davey
Cost-minimization analysis and audit of antibiotic management of bone and joint infections with ambulatory teicoplanin, in-patient care or outpatient oral linezolid therapy
J. Antimicrob. Chemother., February 1, 2003; 51(2): 391 - 396.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.